Background/Objectives: Plasma zinc is an important biomarker of zinc status, but the concentration is depressed by inflammation. Subjects/Methods: Apparently healthy adults, who tested positive twice for human immunodeficiency virus (HIV) but who had not reached stage IV or clinical AIDS, were randomly allocated to receive a food supplement (n ¼ 17 and 21) or the food plus a micronutrient capsule (MN; n ¼ 10 men and n ¼ 33 women) containing 15 mg zinc/day. We used the inflammation biomarkers, C-reactive protein (CRP) and a1-acid glycoprotein (AGP), to identify subjects with and without inflammation and determine the effect of inflammation on the response of plasma zinc concentrations to the MN and food supplements. Results: There were no differences between men and women either in plasma zinc or in the responses to the supplements and their data were combined. Plasma zinc was lower in those with inflammation than without. Repeated measures analysis of variance (ANOVA) showed that inflammation blocked increases in plasma zinc, and there was an approximate 10% increase in plasma zinc concentration in response to the MN supplement (P ¼ 0.023) in those without inflammation. Subgroup analysis showed mean changes in plasma zinc of 0.95 and À0.83 mmol/l (P ¼ 0.031) in response to the MN and food treatments, respectively, in those without inflammation at both time points. Conclusions: Inflammation seems to block any increase in plasma zinc after MN supplement and it is important to identify those without inflammation to determine the effectiveness of a zinc supplementation program.
Introduction
Serum zinc concentration is commonly used to measure zinc status and detect zinc deficiency (Brown, 1998; Hambidge, 2003; Hotz et al., 2003; Hotz and Brown, 2004) ; however, zinc concentrations are depressed by infection and inflammation (Wieringa et al., 2002) . Experiments in humans showed that similar to iron, plasma zinc could be depressed by 50-70% within 24 h after experimental infection in volunteers (Beisel, 1976) . Thus, plasma zinc concentrations will potentially overestimate the extent of zinc deficiency in developing countries in which prevalence of infection is high (Brown et al., 1993; Wieringa et al., 2002; Thurnham et al., 2003) . Excluding samples from an analysis in which evidence of inflammation is present can potentially bias results (Gibson et al., 2008) and can also be impracticable where the prevalence of inflammation is extensive; for example, in a recent study in the Gambia where more that two-thirds of infants at 12 months had raised C-reactive protein (CRP) and a1-acid glycoprotein (AGP; Darboe et al., 2007) .
Zinc is not alone in being influenced by inflammation. Plasma retinol (Thurnham, 1997) , selenium (Galloway et al., 2000) , pyridoxal phosphate (Bates et al., 1999) , ascorbate (Thurnham, 1997) and carotenoids (Thurnham, 2007 ) are a few examples of other important nutritional biomarkers that are affected by infectious processes. For both retinol (Thurnham et al., 2003) and ferritin and possibly other nutritional biomarkers as well , we have shown that the influence of inflammation can be corrected using two acute-phase proteins (APPs), CRP and AGP. In the case of zinc, the acute-phase response leads to a redistribution from the serum (and bone, skin and intestine) to liver, marrow and thymus (Cousins and Leinart, 1988) . Low plasma zinc concentrations are frequently reported in patients with human immunodeficiency virus (HIV; Graham et al., 1991; Baum et al., 1997; Friis and Sandstrom, 2002; Papathakis et al., 2007) but it is less clear whether this is related to HIV positivity, the acute-phase response or both.
CRP and AGP are useful markers of inflammation in apparently healthy people as they provide an indication of the temporal nature of the inflammation relative to the infection. CRP concentrations increase rapidly within a few hours of infection and achieve maximum concentrations in the plasma within 24-48 h and often before the appearance of clinical symptoms (Fleck and Myers, 1985; Calvin et al., 1988) . In contrast, AGP is slower to rise and it may take 4 to 5 days before maximum concentrations are reached (Fleck and Myers, 1985; Stuart and Whicher, 1988) . When clinical symptoms of disease disappear, CRP concentrations fall rapidly, whereas AGP remains elevated during convalescence (Young et al., 1991; Thompson et al., 1992) . Thus, both proteins are elevated immediately after an infection (that is, early convalescence), but when either CRP or AGP are elevated alone, it indicates a subject is in the pre-infection or late convalescent phase, respectively.
In this study, our subjects were all confirmed HIV þ but were apparently healthy at recruitment and we were interested in determining whether they would benefit from a food supplement with or without a multi-micronutrient capsule (MN) by an improvement in zinc status. We recently reported that slightly more than 50% of the recruits showed evidence of inflammation at baseline and that this had changed very little at follow-up , but by correcting for inflammation, the benefits of the iron in the MN capsule could be more clearly showed on ferritin and haemoglobin.
The novelty of this report is that by using both CRP and AGP to detect sub-clinical inflammation, we were able to show an improvement in plasma zinc concentrations in apparently healthy subjects in response to the MN supplement that would otherwise not have been revealed.
Subjects and methods
Full details of the study are described elsewhere (Mburu et al., 2004 . In brief, 180 persons who tested positive for HIV-1 infection on two occasions, (INNOTEST HIV-1/HIV-2 antibody test, Innogenetics, Ghent, Belgium) were recruited into the study. Recruitment of subjects aged between 17 and 54 years took place in two peri-urban centres north of Nairobi : 137 individuals were recruited between February  2002 and January 2003 at Nakuru and 43 others between  October 2002 and March 2003 at Nanyuki. Both centres are in the upper reaches of the Rift Valley Province found within the Central and Midwest Highlands of Kenya. The people were living in their own homes and had not reached stage IV of clinical AIDS by WHO classification. Eligibility criteria for inclusion in the study were HIV positivity, non-pregnant and non-lactating if female, presenting to various HIV-support organizations or a local referral or medical facility. If people were positive for tuberculosis, they had to have received at least 2 months of anti-tuberculosis treatment to be eligible for recruitment. People were additionally excluded if a concurrent illness was present that required ongoing medical intervention, if they presented with clinical AIDS (WHO stage IV), or were already consuming micronutrients, receiving antiretroviral therapy or any other drugs, had no fixed address and were not willing to participate. Once recruited, the subjects received food supplements and softgel capsules. The food comprised 500 g unfortified, unsweetened maize (90%)-soya (10%) blend per day per family. The capsules were taken daily by the recruits and were either placebo or MN. The MN capsule contained 15 mg zinc as zinc glutamate and vitamin A palmitate (800 mgRE), b-carotene (30 mg), cholecalciferol (200 mg), dl-a-tocopheryl acetate, (6.71 mg RRR-a-tocopherol equivalents), vitamin C (70 mg), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), pyridoxine hydrochloride (1.9 mg) and cyanocobalamin (2.6 mg), folic acid (400 mg), iron (30 mg), copper (2 mg), selenium (65 mg) and iodine (150 mg). Ethical approval for the study was obtained from the scientific steering committee of the Kenya Medical Research Institute, the national ethical review board and the contracts review committee of UNICEF East and Southern Africa Regional Office.
Biochemistry
Details of blood collection are described elsewhere . In brief, non-fasted blood samples were collected in the morning. Erythrocyte sedimentation rate was measured on freshly collected blood diluted 4:1 with 109 mmol/l trisodium citrate. A 20 cm Â 2.55 mm column of diluted blood was allowed to stand for 60 min and the column of packed red cells measured to the nearest mm. A general cutoff of 20 mm/h defines high values (Dacie and Lewis, 1995) . Plasma for zinc measurement was collected in 4 ml EDTA vacutainers (Becton Dickinson, Becton Drive, Franklin Lakes, NJ, USA), stored upright in a dark cooler box and processed in the local laboratories within 4 h. Plasma was shipped frozen to Nairobi where it was stored at À20 1C for up to 15 months before analysis. Zinc was determined using a modified atomic absorption method (Shimadzu AA680, Shimadzu Scientific Instruments, Riverwood Drive, Columbia, MD, USA) in plasma diluted 10 times in de-ionized water (Dawson et al., 1968) . The assay was calibrated using Seronorm (Nycomed Parma AS, Oslo, Norway). All measurements were read at 231.09 nm using a gas flow rate of 2.4 l analytical grade acetylene/min and 8 l filtered air/min in the background correction mode. A cutoff threshold of 10 mmol/l was used to define a risk of zinc inadequacy (Mwaniki et al., 2001) .
At the end of the study plasma samples were shipped in dry ice to Northern Ireland and stored at -70 1C for up to a further 2 months before analysis. AGP, CRP and a1-acid glycoprotein (ACT) were measured using DAKO reagents (Dako Ltd, Glostrup, Denmark) using a Hitachi 912 Clinical Analyzer (Roche Diagnostics Ltd, Welwyn, UK). Analysis required o100 ml and plasma was diluted automatically before analysis. Inter-assay precision for each of the APP was p5%. Limits of detection for the APPs were B0.2 g/l for AGP and B0.1 mg/l for CRP. Inflammation was indicated when plasma concentrations of CRP and AGP were 45 mg/l and 41.0 g/l, respectively (Thurnham et al., 2003) and ACT was 40.6 g/l (Paracha et al., 2000) .
Statistics
The zinc data were normally distributed, and hence comparison between treatments or inflammation groups was performed on the raw data and the tables show means and s.d. Plasma zinc concentrations were not different between the sexes and except where specifically mentioned, all calculations were performed on the combined sexes. CRP and AGP were not normally distributed. Data are shown as medians and quartiles and statistics were performed after logarithmic transformation.
Repeated measures analysis of variance (ANOVA) was used on the baseline and 3-month plasma zinc concentrations and between subject variables inflammation and treatment. Inflammation was indicated when CRP was 45 mg/l and/or AGP was 41 g/l. The results of subgroup tests were performed using ANOVA or independent 't' tests as appropriate. Pearson's correlation coefficients were determined for the different inflammatory biomarkers and plasma zinc concentrations at baseline and at 3 months and multiple regression analyses were performed to determine the total variance in plasma zinc concentrations explained by the four inflammatory markers.
Correction of plasma zinc concentrations for current inflammation was performed using correction factors obtained from baseline (n ¼ 163) and 3-month (n ¼ 81) data. Subjects were categorized into four groups defined as: 'reference' in which subjects were characterized by having normal AGP (p1.0 g/l) and normal CRP (p5 mg/l) activity; 'incubation' when CRP was rising (45 mg/l) but AGP was still within the normal range; 'early convalescence', when CRP and AGP (41 g/l) were both elevated; and 'late convalescence' when only AGP was elevated. Correction factors were the ratios of the means of the zinc concentrations of the 'reference' group to the respective inflammatory group. Raw data were corrected by multiplying the individual zinc values in the three subgroups with inflammation by the appropriate correction factor. All analyses were performed using the Statistical Package for Social Sciences (SPSS version 11.0, Woking, Surrey, UK) and differences were considered significant at Po0.05.
Results
Power calculations based on reducing the prevalence of vitamin A deficiency from 46 to 26% with a power of 90 and 5% significance required 86 subjects per arm. We aimed to add 20% to allow for dropouts but recruitment was difficult and by 18 months only 180 people were enrolled. When the first blood was taken, 174 persons were well but insufficient blood and lost or damaged samples prevented some analyses and the results for 163 samples (56 men and 107 women) were the total number obtained at baseline. Only 81 subjects (27 men and 54 women) provided a second blood sample at 3 months. The only evidence we have that compliance was good in the follow-up subjects was a highly significant increase in the mean plasma b-carotene in the group receiving MN supplement from 0.33 to 0.80 mmol/l (Po0.001).
There were no differences at baseline in plasma zinc concentrations between men (mean 9.02, s. Inflammation was associated with significantly lower plasma zinc concentrations in the whole group of subjects at baseline as well as the subgroups who completed and did not complete the study (Table 1 ). In addition, there were no differences in zinc or CRP concentrations between those completing and not completing the study but AGP was significantly higher in the group who failed to complete. There were no differences in zinc, CRP or AGP concentrations between baseline and month 3 for the follow-up subgroup (no shown). However, the presence of inflammation at 3 months depressed the plasma zinc response to the MN supplement. A repeated measures ANOVA found a significant between-subject interaction when inflammation at 3 months and dietary treatment were included in the analysis (P ¼ 0.023; Table 2 ).
As inflammation influenced the zinc response to treatment, plasma zinc concentrations of the different inflammatory groups were examined and correction factors were calculated (Table 3 ). Subgroup analyses indicated that early convalescence and over 3 months were the periods when zinc was most depressed. However, zinc deficiency (o10 mmol/l) was in excess of 60% in all groups. In the follow-up sub-sample, the proportion of low values in the reference group fell by 10% over the supplementation period, but there was a similar increase in numbers of those with inflammation (Table 3) . Abbreviations: AGP, a1-acid glycoprotein; CRP, C-reactive protein.
In addition, a repeated measures ANOVA performed on the plasma zinc sub-sample completing the 3-month supplementation using the presence of absence of inflammation at 3 months as a between-subject variable found evidence of an interaction between time and inflammation (P ¼ 0.18) but no difference over time. A repeated measures ANOVA of the above data found a significant between-subject interaction (P ¼ 0.023) for plasma zinc concentrations (baseline and 3 months), with the between-subject variables inflammation at 3 month (yes or no) and MN supplement (yes or no) and an interaction between plasma zinc and the supplement almost reaching significance (P ¼ 0.06). d Subgroup analyses using paired 't' tests. Because subjects moved between inflammation categories over the 3-month supplementation period, we repeated the analysis shown in Table 2 but grouped subjects into those who were always in the reference group, those who moved out of or went into the reference group and those who showed inflammation at both time points. As before, the presence of inflammation depressed the plasma zinc response to the MN supplement (P ¼ 0.032) and there was a significant difference in the changes in plasma zinc between the MN and food groups in which there was no inflammation (Table 4 ). The MN supplement produced a positive change in plasma zinc concentrations. However, although the mean plasma zinc concentration in the MN-supplemented group with no inflammation was positive, it was not significantly different from the two negative changes in the two groups with inflammation.
There were only weak correlations between plasma zinc concentrations and the different inflammatory markers at both time points (Table 5 ). In addition, multiple regression analysis to determine the contribution of current inflammation to plasma zinc concentrations at baseline and at 3 months in zinc concentrations found in both cases only 14% of the variance in plasma zinc explained. Only 3% of the variance in the change in plasma zinc concentrations was explained by month 3 inflammatory markers.
In the final analysis, we used the correction factors calculated in Table 3 to correct zinc concentrations for the presence of inflammation and increased mean zinc values of the inflammation groups to those of the respective reference groups. After correcting the baseline and month 3 data, repeated measures ANOVA was used to compare the raw and inflammation-corrected data separately for any effects of the dietary supplements on plasma zinc concentrations (Table 6 ). The mean differences in zinc concentrations obtained in subjects who received the MN supplement were both positive and higher than those in the groups receiving food only but none of the differences were significant.
Discussion
Two things were evident from the outset of this work: plasma zinc concentrations were low and, when sub-clinical inflammation was present, plasma zinc concentrations were further depressed. We identified sub-clinical inflammation in the apparently healthy recruits using elevated plasma CRP and AGP concentrations. We have shown that these are useful biomarkers with which to detect current inflammation that There were 31 subjects with no inflammation at both times, 15 subjects had inflammation at one time point only and 35 subjects had inflammation at both time points. The distribution in the micronutrient (MN) and food-only columns were 18 and 13, 7 and 8 and 18 and 17, respectively. c Differences in zinc between baseline and month 3 were examined using repeated measures ANOVA using treatment and inflammation status as between-subject variables. The zinc responses differed between subjects in response to inflammation (P ¼ 0.032). d Changes were calculated by subtracting baseline data from month 3 data. The P-values are differences between treatments (independent 't' tests). Values are means and s.d. b There were 43 subjects who received the micronutrient (MN) and food and 38 subjects in the food-only group. c Repeated measures ANOVA was used to examine the differences between the baseline and month 3 zinc concentrations of the raw and corrected data separately using treatment as a between-subject variable. Similarly, differences between the raw and corrected data were examined using the change data and treatment as a between-subject variable. No significant differences emerged from any of the analyses.
was also influencing plasma micronutrients such as retinol (Thurnham et al., 2003) or ferritin . Using CRP and AGP, we categorized our subjects into the reference group with no raised proteins and three inflammatory groups.
When we analyzed the effect of the MN supplement and sub-clinical inflammation on plasma zinc concentrations, we found that the response to the MN supplement was dependant on the absence of inflammation (P ¼ 0.02), and plasma zinc only increased in those subjects with no inflammation at 3 months (P ¼ 0.07). However, some of the subjects with no inflammation at 3 months may nevertheless have been inflamed at baseline, and hence we refined the analysis and separately analysed those with no inflammation at both time points from those with inflammation at one and two time points. We again found that the plasma zinc response to the MN was dependant on the absence of inflammation (P ¼ 0.04), and we also showed that in the group with no inflammation the change in plasma zinc in response to the MN was significantly greater than that in the group receiving food only (P ¼ 0.03).
In the past, we have calculated correction factors to adjust nutrient concentrations of plasma in subjects with inflammation to make the means of the inflammatory groups comparable with those of the reference groups . We also followed the same method with these zinc data but it did not assist in showing any increase in plasma zinc in response to the MN supplement in comparison with the food only. This may mean that inflammation was actually blocking the uptake of zinc and not just depressing the plasma response. Hence, when we corrected for the depression in plasma zinc, we were not able to reveal the effects of the MN supplement. The explanation for this failure may have something to do with the low plasma zinc concentrations that may be more indicative of a long-term, chronic deficiency of zinc than current inflammation. In this respect, the stronger correlations of plasma zinc with erythrocyte sedimentation rate and AGP than either CRP or ACT may be some support for this idea, as CRP and ACT are markers of current inflammation whereas erythrocyte sedimentation rate and AGP are more strongly associated with chronic inflammation (Jansson et al., 1986; Stuart and Whicher, 1988) .
The low concentration of plasma zinc in the reference group was somewhat lower than that reported in the National Survey in Kenya in 1999 (Mwaniki et al., 2001) . After removing subjects with infection, the researchers reported 44, 52 and 45% prevalences of zinc deficiency in children, women and men, respectively. In the HIV þ women and men in our study, the prevalence of zinc deficiency in the reference groups varied from 61 to 73%. The lower results in our HIV þ subjects may be because of the fact that we collected plasma and not serum. When blood is taken from the same subject, serum zinc concentrations tend to be higher than plasma (Kasperek et al., 1981; English and Hambidge, 1988) . Thus, zinc status of the HIV þ subjects in the reference groups was probably similar to that of non-HIV þ subject in the National Survey, that is, the depression in plasma zinc concentrations was mainly because of a dietary inadequacy of zinc and some inflammation and not HIV sero-positivity per se. Alternative cutoffs based on the 2.5 percentile in the National Health and Nutrition Examination Survey studies (Hotz et al., 2003; Hotz and Brown, 2004) of 10.1 and 10.7 mmol/l (nonpregnant women and men, respectively) would increase these figures slightly, but irrespective of the cutoff used, there is no doubt regarding the poor zinc status of the subjects.
In our baseline sample, approximately 60% of subjects had evidence of inflammation on the basis of elevated CRP and AGP concentrations. Mostly, inflammation was detected using CRP and there were only B10% in which AGP only detected inflammation. The usefulness of a raised AGP concentration however was that when it was combined with a raised CRP, we had the lowest concentrations of plasma zinc. This combination of elevated APPs represents the earliest period of convalescence, that is, the period closest to sickness, and supports the suggestion that the magnitude and change in plasma zinc is related to the stage of infection (Brown, 1998) , and in this case sub-clinical infection. It is interesting that Brown and colleagues did not find any significant reduction in zinc associated with various markers of infection (symptoms, raised CRP, leucocytosis, raised erythrocyte sedimentation rate, history of fever or diarrhoea) in four similar-sized studies on children (Brown, 1998) . Unfortunately none of their studies measured AGP, and hence it is not possible to know the stage of inflammation or the number of subjects in whom AGP alone was elevated that may account for the difference between their studies and ours. Other workers who measured both CRP and AGP in Indonesian infants reported significantly depressed concentrations of plasma zinc concentrations associated with both CRP and AGP, and in 49 (45%) of the 110 infants with inflammation AGP was the only APP that was abnormally raised (Wieringa et al., 2002) .
The low plasma zinc concentrations found in this study and the National survey are mainly due to the diet that is high in maize and legumes. These foods are rich in phytate that chelates dietary zinc and iron and make them nonbioavailable (Gibson and Fergusson, 1998) . The principal cereal eaten by our subjects was maize and analyses of maize kernels, 95% extraction white flour and unleavened corn bread in the Sidama region of Ethiopia to the north of Kenya reported high phytate:molar ratios of 35, 31 and 22 (Abebe et al., 2007) . Phytate:zinc ratios in Kenyan diets are reported to be among the highest in the world (Gibson and Fergusson, 1998; Hotz and Brown, 2004) . Workers examining the diets of toddlers in Kenya reported that 57% of zinc intakes were unlikely to meet basal zinc requirements (Murphy et al., 1992) whereas others have estimated this at 90% (Gibson and Fergusson, 1998) . Conditions such as these make the absorption of zinc very difficult (Hotz and Brown, 2004) .
In Kenya, maize is usually consumed as a thick porridge 'ugali', which is prepared from whole ground white maize in which the maize is unleavened. The food supplement we supplied was also predominantly maize flour and would not have reduced the phytate content of the diet. Others have shown that high phytate meals depress zinc absorption from zinc-fortified foods . In spite of this, there was an approximately 10% increase in plasma zinc in response to the MN supplement in subjects without inflammation.
The high level of phytate in the Kenyan diet probably contributed to both the zinc and iron deficiencies in Kenyan adults and probably reduced absorption of zinc from the MN supplement. We previously showed that the MN supplement increased iron stores in HIV þ subjects with inflammation but use of that iron to synthesize haemoglobin was only possible in those without inflammation . A mechanism by which inflammation may block zinc absorption, in the same manner as hepcidin controls iron (Nemeth et al., 2003) , is not known. Plasma zinc concentrations only represent a small proportion of total body zinc (Aggett and Favier, 1993) and do not reflect zinc stores or functional zinc activity. In fact, zinc concentrations can also vary considerably throughout the day (Hotz et al., 2003; Hotz and Brown, 2004) , and hence it is perhaps not surprising that there was only a small increase in plasma zinc in response to the MN supplement. However, the possible role of inflammation in controlling zinc absorption needs more study.
